Benzothiazolone compound

Abstract

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

1 . A compound which is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof in at least 95% enantiomeric excess. 
     
     
         2 . The compound or a pharmaceutically acceptable salt thereof according to  claim 1 , in at least 98% enantiomeric excess. 
     
     
         3 . The compound or a pharmaceutically acceptable salt thereof according to  claim 1 , in at least 99% enantiomeric excess. 
     
     
         4 . The compound according to  claim 1  (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form. 
     
     
         5 . The compound according to  claim 4 , in at least 98% enantiomeric excess. 
     
     
         6 . The compound according to  claim 4 , in at least 99% enantiomeric excess. 
     
     
         7 . A pharmaceutical composition comprising a therapeutically effective amount of (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers wherein the (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, is present in at least 95% enantiomeric excess. 
     
     
         8 . A pharmaceutical composition according to  claim 7 , wherein the (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, is present in at least 98% enantiomeric excess. 
     
     
         9 . A pharmaceutical composition according to  claim 7  wherein the (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, is present in at least 99% enantiomeric excess. 
     
     
         10 . A pharmaceutical composition according to  claim 7 , wherein the (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form. 
     
     
         11 . A pharmaceutical composition according to  claim 8 , wherein the (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form. 
     
     
         12 . A pharmaceutical composition according to  claim 9 , wherein the (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form.